Parents navigating autism diagnoses face overwhelming decisions about where their children will spend dozens of hours each week learning to communicate, regulate emotions, and build skills for independence. Most assume they’re choosing between local therapy providers. They rarely realize they’re selecting a portfolio company.
Private equity firms have quietly acquired more than 500 autism therapy centers spanning 42 states since 2014, with nearly 80 percent of those purchases compressed into a four-year sprint between 2018 and 2022. The consolidation, documented in a study published January 5 in JAMA Pediatrics, represents one of the first attempts to map how financial investors have reshaped a corner of healthcare that serves some of the country’s most vulnerable children.
Yashaswini Singh, a health economist at Brown’s School of Public Health who led the research, said the acquisitions unfolded largely invisible to families and regulators alike. Private equity-owned clinics face no requirement to disclose ownership changes, forcing her team to reconstruct the landscape through proprietary databases, press releases, and archived websites. They identified 574 centers across 142 separate deals, with California holding 97, Texas 81, and Colorado 38.
Why Autism Therapy Became Attractive to Investors
Autism diagnoses among U.S. children nearly tripled between 2011 and 2022, creating surging demand for Applied Behavior Analysis and related interventions. For investors, that translated into predictable insurance payments—steady revenue streams that make clinics appealing acquisitions. The study found states in the top third for childhood autism prevalence were 24 percent more likely to host private equity-owned centers. Investment also clustered in states with fewer restrictions on insurance coverage for autism services.
Most children receiving these therapies are insured through Medicaid, which adds a wrinkle. If investors push clinics toward more intensive schedules to maximize billing, state budgets absorb those costs. That financial pressure could reshape who receives care, how much they get, and whether treatment decisions prioritize clinical need or reimbursement rates.
“The big takeaway is that there is yet another segment of health care that has emerged as potentially profitable to private equity investors and it is very distinct from where we have traditionally known investors to go, so the potential for harm can be a lot more serious,” Singh explains.
Daniel Arnold, a senior research scientist at Brown who co-authored the study, said his concerns mirror patterns seen when private equity entered nursing homes, emergency departments, and dialysis centers. Those sectors saw cost-cutting measures that sometimes compromised patient outcomes. Whether autism care follows a similar trajectory remains unknown.
What Happens Next Is Anybody’s Guess
The researchers deliberately avoided drawing conclusions about quality. They don’t yet know if private equity ownership improves access by expanding clinic networks or degrades care by prioritizing profit margins. Singh emphasized that modest returns paired with genuine service expansion wouldn’t necessarily harm families. The problem is the data gap.
Her team is seeking federal funding to examine whether ownership changes correlate with longer treatment durations, altered medication patterns, earlier or later diagnoses, or shifts in therapy intensity. For now, the study establishes a baseline, documenting how rapidly financial firms embedded themselves in a system built around children who often struggle to advocate for their own needs.
Families still walk into clinics with the same therapists and familiar waiting rooms. But the financial architecture underneath has been rebuilt by firms more accustomed to boardrooms than behavior plans. Whether that shift ultimately helps or harms remains an open question with potentially serious consequences for millions of children.
JAMA Pediatrics: 10.1001/jamapediatrics.2025.5443
ScienceBlog.com has no paywalls, no sponsored content, and no agenda beyond getting the science right. Every story here is written to inform, not to impress an advertiser or push a point of view.
Good science journalism takes time — reading the papers, checking the claims, finding researchers who can put findings in context. We do that work because we think it matters.
If you find this site useful, consider supporting it with a donation. Even a few dollars a month helps keep the coverage independent and free for everyone.